Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T Cells for Refractory Autoimmune Diseases
NCT06688799Phase 2Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR-T cells in systemic lupus erythematosus (SLE), Sjogren's syndrome, systemic sclerosis (SSc) and 3 more, sponsored by Beijing Gaobo Hospital. Primary endpoints: Dose-limiting toxicity at 28 days, Adverse events at 30 days and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)Sjogren's syndromesystemic sclerosis (SSc)antiphospholipid syndrome (APS)idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT06688799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06688799.